Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 24 Carcinoma, Renal Cell 15 Carcinoma, Non-Small-Cell Lung 15 Neoplasm Metastasis 12 Urinary Bladder Neoplasms 6 Sarcoma 6 Prostatic Neoplasms 6 Lung Neoplasms 6 Pancreatic Neoplasms 5 Neoplasms 5 Kidney Neoplasms 5 Ovarian Neoplasms 4 Glioblastoma 4 Carcinoma, Transitional Cell 4 Uveal Melanoma 3 Small Cell Lung Carcinoma 3 Myelodysplastic Syndromes 3 Mesothelioma 3 Histiocytoma, Malignant Fibrous 3 Colorectal Neoplasms 3 Chordoma 3 Carcinoma, Neuroendocrine 3 Carcinoma, Merkel Cell 3 Breast Neoplasms 3 Brain Neoplasms 3 Urogenital Neoplasms 2 Urethral Neoplasms 2 Ureteral Neoplasms 2 Triple Negative Breast Neoplasms 2 Thyroid Neoplasms 2

Interventions

Oxaliplatin 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Advanced NSCLC × Ipilimumab × Clear all

NCT04043195 2025-05-28

NSCLC

University of California, San Diego

Phase 1/2 Active not recruiting

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡